Pfizer Q2 FY26 swings to net loss of USD 248 million; revenue rises 3% to USD 15 billion

• Pfizer posted Q2 2026 revenue of USD 15 billion, up 3% year over year, with reported diluted EPS turning to a loss of USD 0.04.
• Adjusted diluted EPS (non-GAAP) slipped to USD 0.77 from USD 0.78, while reported results reflected USD 4.3 billion of non-cash intangible asset impairments.
• Raised 2026 revenue guidance midpoint by USD 0.5 billion to USD 60.5 billion-USD 62.5 billion, citing stronger non-COVID products.
• Reaffirmed 2026 adjusted diluted EPS (non-GAAP) at USD 2.8-USD 3, absorbing an expected USD 0.10 hit tied to the Innovent transaction.
• Albert Bourla said launched and acquired products performed well, with momentum in obesity programs and oncology remaining a source of strength.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804345420) on August 04, 2026, and is solely responsible for the information contained therein.